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Summary
Objective: Calcitonin (CT) has been recently shown to exhibit direct protective effects on articular cartilage against joint degenerative disease.
It has been proposed that CT might act via the CT receptor (CTR) to activate the cyclic AMP (cAMP) pathway and protect type II collagen
degradation. In this study, we investigated the existence of CTR in human articular cartilage and chondrocytes, and examined the potential
pharmacological effects and transduction pathway of salmon CT (sCT) in human chondrocytes.
Methods: Five human articular cartilage samples were examined for the expression of the CTR by polymerase chain reaction (PCR), immuno-
staining and Western blot analysis. cAMP levels in human chondrocyte stimulated with sCT were assessed by ELISA. The effect of sCT on the
gene expression proﬁles, including aggrecan, type II collagen, MMP-1, MMP-3 and MMP-13, of human chondrocytes was also examined by
relative quantitative Real-time PCR.
Results: We failed to detect the CTR at both the transcriptional and protein levels in human chondrocytes and cartilage tissue by PCR, im-
munostaining and Western blotting. cAMP levels were signiﬁcantly elevated in human chondrocytes by forskolin (100 mM) to more than 10-fold
(P< 0.001), however, were not induced by sCT (107 M, 108 M, 109 M). Real-time PCR analysis demonstrated that sCT slightly reduced the
gene expression of MMPs, although this effect was not statistically signiﬁcant.
Conclusion: In contrary to previous reports, our data indicate that human cartilage and chondrocytes do not express CTR. Furthermore, sCT
does not appear to have direct effects on human chondrocytes. We propose that the chondroprotective effect of CT observed in vivo may be
indirect via its impact on subchondral bone resorptive activity of osteoclasts.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Calcitonin (CT) is a 32-amino acid peptide hormone which
regulates serum calcium levels. The principal function of
CT is to maintain calcium homeostasis by directly inhibiting
osteoclast-mediated bone resorption and enhancing renal
calcium excretion1e3. It is well established that CT can be
used for the treatment of osteoporosis and Paget’s disease,
principally owning to its inhibitory effect on osteoclastic
bone resorption, regulation of mineral metabolism and anti-
nociceptive properties4. Recent interest has focused on its
application in the treatment of osteoarthritis (OA). CT has
been shown to be effective in preventing cartilage degrada-
tion and relieving pain, suggesting that it might be an ideal
pharmacological treatment forOA5,6. Clinical trials of patients
with spinal collapseandkneeOAsuggest thatCThasananti-
nociceptive effects, as evidenced by the reduced consump-
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450women showed a reduction in the excretion of biochemical
markers of cartilage degradation following 3 months of CT
treatment9. Furthermore, in a double-blind clinical trial of pa-
tients with knee OA, a 1-mg dose of salmon CT (sCT) signif-
icantly decreased Lequesne’s algofunctional index scores,
and the levels of serum and urinary C-terminal peptide of
type II collagen. Taken together, these data suggest that in
addition to symptom-modifying effects, CTmay also improve
articular joint function by attenuating cartilage degradation10.
Hence, direct chondroprotective and chondrotheraputic
potential of CT have been proposed11.
Inspired by the clinical observation, a number of studies
have recently been conducted to reveal its physiological im-
pact on cartilage and chondrocytes. Studies by Sonder-
gaard et al. (2006) demonstrated the existence of CT
receptor (CTR) in bovine cartilage by immunohistochemis-
try and suggested that CT may directly inhibit collagenase
activity by binding to CTR and activating the cyclic AMP
(cAMP) pathway, causing a reduction in type II collagen
degradation in bovine cartilage12. Similarly, it has been re-
ported that CT stimulates calcium efﬂux, increases cAMP
level by 2- to 3-fold, and enhances collagen synthesis in
rabbit chondrocyte cultures13. Studies employing isolated
chondrocytes or cartilage explants from animals have also
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chondrocyte proliferation, cartilage formation and matura-
tion14e19. In humans, addition of CT to chondrocyte cluster
cultures increased type II collagen and proteoglycan con-
tent in culture medium, but did not enhance cell prolifera-
tion16. Other reported effects of CT include an increase of
phospholipase A2 (PLA2) activity, an inﬂammatory enzyme
in OA, and a decrease of collagenolytic activity in isolated
human OA chondrocytes in vitro20.
Although several positive effects of CT treatment on
chondrocytes have been demonstrated, the biological
mechanism underlying its potential direct effects on human
cartilage and chondrocytes remains unclear. It is well ac-
cepted that CT acts through the binding to the CTR and
subsequently elicits adenylate cyclase activation. Previous
studies indicate that CTR is expressed in a wide number
of tissues including the central nervous system, ovary, tes-
tis, renal epithelial cells and osteoclast (Quinn et al., 1999).
Recently, Sondergaard et al. (2006) demonstrated the pres-
ence of CTR in bovine cartilage tissue12, however, the pres-
ence of CTR in human articular cartilage tissue has not
been conﬁrmed. In this study, we investigated the expres-
sion of CTR in human cartilage and isolated chondrocytes
and examined whether CT has a direct functional role in
human articular chondrocytes.Methods and materialsTISSUE HARVESTHuman articular cartilage from specimens of femoral condyle was ob-
tained from patients (N¼ 5, average age¼ 67.4 3.8) undergoing total
knee replacement surgery at the Hollywood Private Hospital, Western Aus-
tralia. This tissue was used for RNA extraction and chondrocyte culture. Nor-
mal articular cartilage tissues (N¼ 3) were obtained from the non-OA
patients undergoing arthroscopy for autologous chondrocyte implantation
for knee injury. The acquisition of human tissue was approved by the Human
Research Ethics Committee of the University of Western Australia.CHONDROCYTE CULTUREChondrocytes were isolated from fresh cartilage tissue and cultivated
in vitro. Specimens were manually dissected into 200e500 mm pieces before
undergoing enzymatic digestion by type II collagenase (400 units/ml) in an or-
bital mixer incubator at 130 rpm at 37C for 6 h. Matrix digestion was termi-
nated by the addition of fetal bovine serum (FBS). Tubes were centrifuged
at 1500 rpm for 8 min then washed twice in serum-free medium. Cells were
then resuspended in a tissue culture ﬂask at a density of 5 104 cells/ml
and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM/F-12; Gibco,
New York, USA) supplemented with 20% fetal calf serum (FCS; TRACE, Syd-
ney, Australia), 0.1% gentamycin and 50 mg/ml L-ascorbic acid (Gibco, New
York, USA) at 37C in a humid environment with 5%CO2. The culture medium
was changed every 2 days. Once chondrocyte conﬂuencewas achieved, cells
were either lysed for further RNA/protein extraction or harvested for passage
using trypsin. Primary chondrocytes were used for CTR detection by polymer-
ase chain reaction (PCR) and Western blotting, whereas sCT treatment was
preformed on ﬁrst passage subcultured chondrocytes.RNA EXTRACTION AND REVERSE TRANSCRIPTION RT-PCRQiagen RNeasy Mini kit (Qiagen) was used to extract RNA from human
cartilage tissue and isolated human chondrocytes. Cartilage tissues were
pulverized in liquid nitrogen followed by RNA extraction with the RNeasy
Mini kit according to the manufacturer’s instruction. Cells were washed with
1 phosphate buffered saline (PBS) and processed according to the kit’s in-
struction. RNA from human giant cell tumor (GCT) tissue was also extracted
and served as a source of human osteoclasts and thus a positive control.
First strand synthesis was carried out using 2 ml of RNA from each sample,
600 U of M-MLV reverse transcriptase, 60 U of RNasin ribonuclease inhib-
itor, 15 mM dNTP (Promega), and 300 mm Oligo dT in a total volume of 20 ml.
PCR was performed using 2 ml of the ﬁrst strand product in a 20-ml reaction
volume containing 10 ml of 2 GoTaq Green Mix (Promega Corp., Madison,
WI, USA), 1 ml of each primer (CTR: forward: 50-CTGGGAATCCAGTTT
GTCGT-30, reverse: 50-CGCTGGTTCCACTGAATTTT-30; CRLR: forward:50-AACAGAACCTGGGATGGATG-30, reverse: 50-TCTGTTGCTTGCTGGA
TGTC-30). The reaction mixture was heated at 95C for 3 min to denature
the DNA and then subjected to 35 cycles of PCR (94C for 40 s, 60C for
40 s, 72C for 40 s) followed by a ﬁnal extension at 72C for 7 min. House-
keeping gene 18S was used as an internal control. PCR products were
analysed by electrophoresis in 2% agarose gel.WESTERN BLOT ANALYSIS OF CTRWestern blot analysis was used to conﬁrm the expression of CTR in hu-
man cartilage. Cells were seeded in a T25 ﬂask and grown to conﬂuence.
Primary chondrocytes were then harvested and lysed using modiﬁed Ripa
lysis buffer (5% Tris/pH¼ 7.5, 15% NaCl, 1% Nonidet P-40/IGEPAL, 0.1%
sodium dodecyl sulphate, and 1% deoxycholate) supplied with Sigma-
FAST protease inhibitor solution (1:100; SigmaeAldrich, UK). GCT tissue
was used as positive control in the assay. Thirty micrograms of each protein
lysate were electrophoresed onto a nitrocellulose gel and probed with
a 1:500 dilution of primary rabbit polyclonal anti-CTR antibody (Abcam,
ab11042) and secondary rabbit IgG. Alpha-tubulin (1:2000; SigmaeAldrich,
UK) was utilized as an internal control. The membrane was then exposed
to Western blotting detection reagents (Amersham, UK) and visualized by
exposure to an LAS-3000 imaging system (Fuji Photo Film Co., Ltd., Japan).IMMUNOSTAINING FOR CTRImmunohistochemistry was performed on human giant cell tumour (hGCT)
of bone,which is known toexpressCTR21 andnormal humanarticular cartilage
sections to further assess the presence of CTR. GCT tissue was moistened
with PBS and evenly imprinted onto glass slides. Imprints were then ﬁxed in
4% paraformaldehyde for 20 min at room temperature. The cartilage tissue
was ﬁxed in 4%paraformaldehyde, embeddedwith parafﬁn, and subsequently
sectioned. Parafﬁn embedded sections were treated with 0.25% trypsin to en-
hance antigen presentation, followed by deparafﬁnization and rehydration.
Each slide was then blocked for endogenous peroxidase activity by incubation
in 3% H2O2 for 10 min, washed in Tris-buffer saline (TBS), and then pre-incu-
bated with 20% FBS for 30 min followed by incubation with a 1:100 dilution of
the primary anti-CTRantibody at 4C ina humidiﬁed chamber overnight. Slides
were subsequently incubated with anti-rabbit Ig antibody (Dako Pty Ltd., Aus-
tralia) followed by three 5-minwashes in TBS, then color developed for 5 min in
a moist chamber at room temperature using a liquid 3,30-diaminobenzidine
(DABþ) substrateechromogen solution kit (Dako Pty Ltd., Australia). The
preparation inwhich the primary antibody toCTRwas omitted served as a neg-
ative control. Slides were counterstained in hematoxylin and mounted in De-
pex mounting medium. GCT imprints were co-stained with tartrate-resistant
acid phosphatase (TRAP) to identify the osteoclast-like giant cells.cAMP ELISA ASSAYIt is well established that CT elevates intracellular cAMP in various cell
types. In this study, we employed an Enzyme Immunoassay kit (Assay De-
signs Inc., Michigan, USA) to detect intracellular cAMP levels in chondro-
cytes after sCT stimulation. Human chondrocytes (passage 1) were
cultured in 24-well plates and maintained in serum-free culture medium for
12 h. Cells were then pretreated with 100 mM of cAMP phosphodiesterase in-
hibitor 3-isobutyl-1-methylxanthine (IBMX; SigmaeAldrich, UK) for 20 min,
and subsequently stimulated with sCT (107 M, 108 M, 109 M), or
100 mM forskolin (SigmaeAldrich, UK) for 30 min. The cAMP contents from
supernatant and cell lysis were measured using the cAMP Enzyme Immuno-
assay kit (Assay Designs Inc., Michigen, USA) according to the manufactur-
er’s instructions. The optical density was read at 405 nm in a POLARstar
OPTIMA multifunction microplate reader (BMG Labtech, Germany). The con-
centration of cAMP was calculated from the raw data using a cAMP standard
curve. All experiments were carried out in triplicate.REAL-TIME PCR AND DATA ANALYSISTo measure the gene expression proﬁle of chondrocytes following sCT
treatment, relative quantitative Real-time PCR was performed on a 384-
well plate ABI Prism 7000 Sequence Detection machine (Applied Biosys-
tems, USA) using SYBR Green PCR Master Mix (Applied Biosystems,
USA). Human chondrocytes at ﬁrst passage were seeded on a 6-well plate
and pretreated with sCT at 108 M for 24 h, then collected for RNA extraction
and reverse transcript reaction. The total volume of each PCR reaction was
10 ml, which contained 5 ml of SYBR Green PCR Master Mix, 2.5 ml of ddH2O,
1.5 ml of cDNA, and 5 mM of each of the forward and reverse primers
(Table I). Real-time PCR was carried out at 95C for 10 min (activation),
40 cycles of 95C for 15 s, 60C for 20 s and 72C for 20 s (ampliﬁcation)
and 72C for 1 min (ﬁnal extension). Housekeeping gene (18S) was always
included in the same plate as an internal control. A cycle threshold (Ct) value
was obtained for each sample and analysed by the Sequence Detection Sys-
tem software (Applied Biosystems). The comparative 2DDCT method was
Table I
Primer sequences used for Real-time PCR (annealing temperature: 60(C)
Gene Accession no. Primer sequences Size
Aggrecan M55172 Fw*: TCCCCTGCTATTTCATCGAC 117
rvy: CCAGCAGCACTACCTCCTTC
Type II Collagen NM_001844 fw: CTGGAAAAGCTGGTGAAAGG 105
rv: GGCCTGGATAACCTCTGTGA
MMP-1 NM_002421 fw: AGGTCTCTGAGGGTCAAGCA 82
rv: CCAGGTCCATCAAAAGGAGA
MMP-3 NM_002422 fw: GAAGCTGGACTCCGACACTC 88
rv: GATCCAGGAAAGGTTCTGA
MMP-9 NM_004994 fw: GATGCGTGGAGAGTCGAAAT 87
rv: CTATCCAGCTCACCGGTCTC
MMP-13 NM_002427 fw: TTGAGCTGGACTCATTGTCG 84
rv: TGCAAACTGGAGGTCTTCCT
18S X03205 fw: CCTGCGGCTTAATTTGACTC 119
rv: AACTAAGAACGGCCATGCAC
*Forward.
yReverse.
452 Z. Lin et al.: Calcitonin receptor in human cartilage and chondrocytesused to calculate the relative expression of each target gene as previously
described22. Brieﬂy, mean Ct value of target genes in the treated group
was normalized to its averaged Ct values of the housekeeping gene 18S
to give a DCt value, which was further normalized to control samples to ob-
tain a DDCt value. The untreated group was used as reference sample.Fig. 1. The mRNA expression of CTR in human cartilage and chondrocyte
layer with spherical phenotype. (B) The gene expression of CTR in ﬁve ind
Articular cartilage samples were taken from OA patients undergoing total j
and cultured in vitro. RNA extracted from human GCT served as positive
the human cartilage tissue or isolated chondrocytes. HoSTATISTICAL ANALYSESData are presented as means SEM. Statistical analysis was performed
by Student’s t test using the SPSS12.0 software (SPSS Inc., USA). P values
less than 0.05 were considered signiﬁcant.s. (A) Primary human chondrocytes (passage 0) cultured on mono-
ividual human cartilage tissue samples and cultured chondrocytes.
oint replacement. Chondrocytes were isolated from human cartilage
control. CTR (200 bp) is expressed in human GCT, but not in any of
usekeeping gene 18S served as internal control.
453Osteoarthritis and Cartilage Vol. 16, No. 4ResultsIDENTIFICATION OF THE CTR IN HUMAN CARTILAGE
AND CHONDROCYTESAs an initial effort to investigate whether human chondro-
cytes express CTR in vitro or in vivo, RT-PCR was used to
detect the expression of CTR mRNA in human articular car-
tilage and isolated chondrocytes [Fig. 1(A)]. Primer se-
quences were speciﬁcally designed and blasted to match
the human CTR sequence. Given that two human CTR iso-
forms (C1a and C1b) have been identiﬁed23,24, the PCR
primers for human CTR were selected to ﬂank the consen-
sus region of all given splice variants. As shown in Fig. 1(B),
the expression of CTR was clearly detected in human oste-
oclast-like cells derived from GCT, however, no message
was observed in human cartilage and chondrocyte samples
even under saturating conditions of PCR cycling (i.e., 35
cycles). 18S was served as a housekeeping gene to ensure
equivalent loading of samples.
Next, we examined for the expression of CTR at the pro-
tein level in human chondrocytes and cartilage tissues. For
this purpose, a rabbit polyclonal antibody to human CTR
which, recoginises an epitope within the cytoplasmic do-
main that is identical to both C1a and C1b isoforms, was
used. Consistent with our PCR results, Western blot analy-
ses revealed abundant expression of human CTR in hGCT
(56.9 kDa), but not in the primary chondrocytes at equiva-
lent protein levels (Fig. 2). Western blot analysis conducted
on the receptor activator of nuclear factor-kappa B ligand
(RANKL) stimulated RAW264.7 cell cultures, which are
known to abundantly express CTR25, showed very weak
expression levels 5 days post-culture (data not shown),Fig. 2. Western blot analysis of CTR in human giant cell tumor and
primary chondrocytes. A band representing CTR appears at
w56.9 kDa only in human GCT tissue. Thirty micrograms of GCT
and chondrocyte samples were resolved by SDS-PAGE and trans-
ferred overnight onto nitrocellulose before being probed for CTR
with speciﬁc antibodies. Alpha-tubulin served as an internal loading
control.suggesting that this antibody is preferentially speciﬁc to hu-
man but not to mouse CTR.
Immunohistochemical analysis further conﬁrmed the ab-
sence of CTR expression in both chondrocytes and cartilage
tissues. As shown in Fig. 3, osteoclast-like giant cells from
hGCT imprints stained positively for CTR [Fig. 3(A)]. Osteo-
clast-like cells were conﬁrmed by positive reaction to TRAP
[Fig. 3(B)]. CTR immunostaining was predominantly local-
ized to the osteoclast cell surface and appeared highly spe-
ciﬁc. When the primary antibody was omitted, no speciﬁc
staining was detected in osteoclasts [Fig. 3(C)]. Analysis of
human joint tissue by immunohistochemical staining with
anti-CTRantibody revealed no speciﬁcCTRstaining in either
cartilage or chondrocytes [Fig. 3(D, E)], whilst multinucleate
osteoclasts in the subchondral bone region (indicated by
arrow) were clearly stained with CTR antibody [Fig. 3(F)].EXPRESSION OF CTR-LIKE RECEPTOR IN HUMAN
CHONDROCYTESGiven that CT has been previously shown to effect chon-
drocytes and cartilage, we next explored the possibility that
it might act through an alternative receptor on chondro-
cytes. The CTR-like receptor (CRLR) exhibits more than
50% identity with CTR, therefore we studied the expression
of CRLR in human cartilage and chondrocytes by RT-PCR.
The same tissue and cultured chondrocyte samples were
subjected to PCR using primers speciﬁc to CRLR. GCT
RNA was used as a positive control. As shown in Fig. 4,
CRLR was absent in all human cartilage samples, however,
CRLR was weakly expressed in expanded chondrocyte cul-
tures. This expression became more evident in late pas-
saged chondrocytes suggesting its expression correlated
with chondrocyte de-differentiation in vitro.INTRACELLULAR cAMP CONCENTRATIONHaving clearly demonstrated that both human cartilage
and chondrocytes lack CTR, we next asked whether CT di-
rectly effected chondrocytes in vitro. To this endweemployed
a cAMP assay to measure intracellular responses to CT. As
shown in Fig. 5, sCT failed to elicit a elevation in cAMP in hu-
man chondrocytes over a range of concentration (107 M,
108 M, or 109 M). On the other hand, forskolin (100 mM),
a non-receptor speciﬁc cAMP activator, clearly elevated
cAMP levels in chondrocytes by more than 10-fold.EXAMINATION OF THE EFFECTS OF sCT ON THE GENE
EXPRESSION OF HUMAN CHONDROCYTESTo further investigate whether CT has any direct effect on
human cartilage or chondrocytes, human chondrocytes
were treated with sCT at a dose of 108 M for 24 h, and
Real-time PCR was used to study the expression of various
cartilage extracellular matrix proteins (aggrecan and type II
collagen) and several Matrix Metalloproteases (MMP-1,
MMP-3, MMP-13). As shown in Fig. 6, the matrix molecules
aggrecan and type II collagen showed similar levels of gene
expression with or without sCT treatment. sCT slightly de-
creased the expression of MMPs, however, this effect was
minimal and did not reach statistical signiﬁcance (P> 0.05).Discussion
The present study was prompted by results of re-
cent clinical studies, suggesting that CT is a potential
Fig. 3. Immunodetection of CTR in human GCT and articular cartilage. (A) Immunostained osteoclast in human GCT imprint, hematoxylin
counterstain, immunostaining is predominantly on the osteoclast plasma membrane (original magniﬁcation, 400); (B) immuno- and
TRAP-staining of osteoclasts in human GCT imprint (original magniﬁcation, 400); (C) negative control without primary antibodies in a human
GCT imprint, hematoxylin counterstain (original magniﬁcation, 400); (D) full thickness of human articular cartilage section with subchondral
bone, immunostained with anti-CTR antibody and counterstained with hematoxylin (original magniﬁcation, 40); (E) chondrocytes in the same
section show no speciﬁc staining, hematoxylin counterstain (original magniﬁcation, 400); (F) osteoclasts (as indicated by arrow) in the sub-
chondral bone region stained positive for CTR (original magniﬁcation, 400).
454 Z. Lin et al.: Calcitonin receptor in human cartilage and chondrocytespharmacological treatment for patients with OA. It has been
previously demonstrated that CT has direct effects on artic-
ular cartilage and attenuation of cartilage degradation via
interaction with the CT receptor10. Surprisingly, in this study
we failed to detect obvious gene expression of CTR mRNA
in either human cartilage or chondrocytes. This result wasstrengthened by the lack of detectable CTR protein in nor-
mal human articular cartilage as evidenced by Western blot-
ting and immunohistochemistry. Furthermore, cAMP ELISA
assays demonstrated that CT did not elict a cAMP response
in human chondrocytes over a range of physiological
concentrations. Real-time PCR also revealed that sCT
Fig. 4. The mRNA expression of CRLR in human GCT, human car-
tilage and chondrocytes. CRLR is abundantly expressed in human
GCT and cultured chondrocytes (passage 1), but absent in human
cartilage tissue.
455Osteoarthritis and Cartilage Vol. 16, No. 4treatment had little to no effect on the expression levels of
cartilage matrix proteins, aggrecan and type II collagen,
and their associated proteases (MMP-1, MMP-3, MMP-13)
in human chondrocytes. Together, these results suggest
that the previous reported effects of CT on chondrocytes
may occur through a mechanism independent of direct
interaction with the CTR. Our study challenges the
contempory hypothesis that CT directly mediates attenua-
tion of cartilage degradation.
The results of this study are in direct contrast to the re-
cent study by Sondergaard et al. who demonstrated the
gene expression of CTR and positive immunostaining of
CTR in bovine articular cartilage12. The reason for this dis-
crepancy is presently unclear, although it may be attributed
to species differences and the primers used. It is possible
that the use of human primer sequences (sense: 50-GA
CAACTGCTGGCTGAGTG-30, anti-sense: 50-GAAGCA
GTAGATGGTCGCAA-30) to amplify the bovine CTR may
result in false positives and thus account for the detected
transcript by Sondergaard et al.12. Alternatively, the tissue
distribution of CTR might simply vary between species. A
nother possibility may be due to the age difference in the tis-
sue origin. Histochemical analysis of pCTR/lacZ expression
in transgenic embryos and foetuses of mice revealed that
CTR expression was positive in cartilage primordium of
the humerus and ears during fetal development, which is,
however, not observed in adult tissue4. It is plausible thatFig. 5. cAMP response of chondrocytes to sCT. Human chondro-
cytes (passage 1) isolated fromOA cartilage were cultured onmono-
layer and stimulated with sCT (107 M, 108 M, and 109 M) or
forskolin (100 mM) for 30 min. The cAMP content from culture super-
natant and cell lysis were both measured. sCT does not change the
cAMP content in chondrocyte compared to vehicle treatment (IBMX/
100 mM), however, forskolin signiﬁcantly elevates the cAMP level
(P< 0.001).the expression of CTR varies in human with age. However,
due to ethical restrictions, human cartilage samples can
only be obtained from adults. Thus, we are unable to di-
rectly compare the expression level of CT in cartilage
from infants.
Previously, CT has been shown to promote cell prolifera-
tion of expanded chondrocyte cultures26. Addition of CT
has also been shown to enhance chondrocyte adhesion to
extracellular matrix in the high-density cultures and alter
the regulation of protease synthesis20. PLA2 activity of hu-
man chondrocytes has also been shown to be elevated
upon sCT stimulation in vitro20. The presence of CRLR in
subcultured chondrocyte reported in this study might in part
account for the positive CT response observed in chondro-
cyte cultured in vitro. CRLR is a member of the G-protein-
coupled receptor family which exhibits up to 55% amino
acid identity with the CTR. Our data indicate that CRLR is
upregulated in monolayer cultured chondrocytes. Given
that the CRLR has been reported to interact with other
members of the G-coupled protein family, including CT-
gene-related peptides and adrenomedullin27, it is tempting
to speculate that CRLR might serve as a non-speciﬁc recep-
tor for CT in isolated human chondrocytes where CTR is
absent. Interestingly, CRLR was not expressed in either car-
tilage tissue or primary chondrocytes suggesting that it might
be involved in the de-differentiation process of in vitro cul-
tured chondrocytes. Further study is required to compare
the physiological responses of late passage chondrocyte cul-
tures with CT addition.
Despite encouraging evidence of CT treatment for OA,
there are large differences between the pharmacological
action and the potential presence of receptors. Animal stud-
ies suggest that CT treatment reduced the progression of
cartilage damage by preventing the loss of collagen, hyalur-
onan and proteoglycan aggregates28e31. A recent pub-
lished study on a rabbit model of surgical-induced OA
demonstrated that daily intramuscular injection of sCT helps
to minimize cartilage degeneration, osteophyte formation
and subchondral cyst formation11. Furthermore, patients
with regular oral CT treatment have less C-terminal peptide
of type II collagen, one of the predominant components of
articular cartilage matrix, in serum30, However, in the sys-
temic models, it is difﬁcult to distinguish whether this chon-
droprotective effect is due to direct or indirect action. Since
CTR expression is not found in human cartilage and chon-
drocytes, the effect of CT on cartilage matrix might be inde-
pendent from chondrocytes. We believe that the beneﬁcial
impact of CT on articular cartilage and chondrocyte is
more likely a secondary effect.
The concept of using CT as a pharmacological treatment
for OA was initially proposed based on its effects on bone
remodeling and mineral metabolism5. Conventionally, OA
has been considered to be primarily a cartilage disorder
with hyaline articular cartilage loss and matrix destruction.
A more comprehensive deﬁnition of the disease addresses
OA as a whole organ disease involving multiple changes in
cartilage, subchondral bone, periarticular muscle, liga-
ments, synovium and the neurosensory system32. In partic-
ular, increased subchondral bone turnover compromised by
speciﬁc architectural changes is an essential part of prog-
ress of the disease. Although there is no conclusive report
about whether subchondral bone loss occurs prior to the
cartilage degeneration in OA, it is well acknowledged that
the functional integrity of articular cartilage largely depends
on the mechanical properties of the underlying subchondral
bone. Manicourt et al. reported that the urinary level of de-
oxypyridinoline, a speciﬁc marker of bone resorption,
Fig. 6. The expression proﬁles of chondrocytic genes (aggrecan, Type II collagen, MMP-1, MMP-3, MMP-13) in sCT treated human chondro-
cytes (passage 1) by Real-time PCR. Mean Ct value of target genes was normalized to it housekeeping gene 18S. Statistic signiﬁcances were
calculated by Student’s t test. Results are shown as mean SEM. P< 0.05 is considered statistically signiﬁcant.
456 Z. Lin et al.: Calcitonin receptor in human cartilage and chondrocytessigniﬁcantly diminished in surgical-induced OA models by
3 weeks subcutaneous injection with CT31. Similarly, histo-
morphometric studies have shown that CT treatment sup-
pressed the loss of subchondral trabecular bone induced
by anterior cruciate ligament transaction in dog models29.
The study suggested that the protective effect of CT on sub-
chondral trabecular bone subsequently safeguarded the
cartilage from degeneration caused by excessive mechani-
cal forces. Additionally, the severity of synovitis in an OA
animal model treated with CT has been shown to be re-
duced as evidenced by decreased serum content of anti-
genic keratan sulfate and hyaluronan31. These studies
suggest that CT might confer therapeutic beneﬁt to the pa-
tients with OA by ameliorating subchondral bone disruption
and/or suppressing joint inﬂammation. These effects might
be independent from articular chondrocytes.
In conclusion, this study demonstrates that CTR is not de-
tectable in human cartilage or chondrocytes. It suggests that
the action of CT on cartilage may be indirect via inhibition of
subchondral osteoclastic bone resorption. We believe that
the information obtained in this study is important for the fur-
ther understanding of CT and its biological behavior, espe-
cially on human cartilage and chondrocytes, and for the
development of potential pharmacological treatment for artic-
ular degenerative diseases.
Acknowledgments
This work was supported by a National Health and Medical
Research Council development grant to M. H. Zheng and
D. J. Wood. Real-time PCR was performed in the Australian
Neuromuscular Research Institute, University of Western
Australia. The authors would like to thank Prof. T. J. Martin
for his critical comments on the work.References
1. Friedman J, Raisz LG. Thyrocalcitonin: inhibitor of bone resorption in tis-
sue culture. Science 1965;150:1465e7.
2. Raisz LG, Niemann I. Early effects of parathyroid hormone and thyrocal-
citonin on bone in organ culture. Nature 1967;214:486e7.3. Warshawsky H, Goltzman D, Rouleau MF, Bergeron JJ. Direct in vivo
demonstration by radioautography of speciﬁc binding sites for calcito-
nin in skeletal and renal tissues of the rat. J Cell Biol 1980;85:682e94.
4. Pondel M. Calcitonin and calcitonin receptors: bone and beyond. Int J
Exp Pathol 2000;81:405e22.
5. Manicourt DH, Devogelaer JP, Azria M, Silverman S. Rationale for the
potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal
Interact 2005;5:285e93.
6. Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K,
Altman RD, et al. Calcitonin is involved in cartilage homeostasis: is
calcitonin a treatment for OA? Osteoarthritis Cartilage 2006;14:
617e24.
7. Badurski J, Jeziernicka E, Naruszewicz K, Racewicz A. Comparative
analysis of three treatment regimens for treating gonarthritis with cal-
citonin, naproxen and ﬂavonoids based on EULAR criteria and visual
analogue scale (VAS). Pol Tyg Lek 1995;50:37e40.
8. Punzi L, Schiavon F, Cavasin F, Ramonda R, Gambari PF, Todesco S.
The inﬂuence of intra-articular hyaluronic acid on PGE2 and cAMP of
synovial ﬂuid. Clin Exp Rheumatol 1989;7:247e50.
9. Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M,
Mindeholm L, et al. Oral salmon calcitonin induced suppression of
urinary collagen type II degradation in postmenopausal women:
a new potential treatment of osteoarthritis. Bone 2005;37:425e30.
10. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP.
Oral salmon calcitonin reduces Lequesne’s algofunctional index
scores and decreases urinary and serum levels of biomarkers of
joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:
3205e11.
11. Papaioannou NA, Triantaﬁllopoulos IK, Khaldi L, Krallis N, Galanos A,
Lyritis GP. Effect of calcitonin in early and late stages of experimen-
tally induced osteoarthritis. A histomorphometric study. Osteoarthritis
Cartilage 2007;15:386e95.
12. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S,
Qvist P, et al. Calcitonin directly attenuates collagen type II degrada-
tion by inhibition of matrix metalloproteinase expression and activity in
articular chondrocytes. Osteoarthritis Cartilage 2006;14:759e68.
13. Deshmukh K, Kline WG, Sawyer BD. Effects of calcitonin and parathy-
roid hormone on the metabolism of chondrocytes in culture. Biochim
Biophys Acta 1977;499:28e35.
14. Lyritis G, Boscainos PJ. Calcitonin effects on cartilage and fracture heal-
ing. J Musculoskelet Neuronal Interact 2001;2:137e42.
15. Ishikawa Y, Wu LN, Genge BR, Mwale F, Wuthier RE. Effects of calci-
tonin and parathyroid hormone on calciﬁcation of primary cultures of
chicken growth plate chondrocytes. J Bone Miner Res 1997;12:
356e66.
16. Franchimont P, Bassleer C, Henrotin Y, Gysen P, Bassleer R. Effects of
human and salmon calcitonin on human articular chondrocytes culti-
vated in clusters. J Clin Endocrinol Metab 1989;69:259e66.
17. Di Nino DL, Linsenmayer TF. Positive regulation of endochondral carti-
lage growth by perichondrial and periosteal calcitonin. Endocrinology
2003;144:1979e83.
457Osteoarthritis and Cartilage Vol. 16, No. 418. Burch WM, Corda G. Calcitonin stimulates maturation of mammalian
growth plate cartilage. Endocrinology 1985;116:1724e8.
19. Burch WM. Calcitonin stimulates growth and maturation of embryonic
chick pelvic cartilage in vitro. Endocrinology 1984;114:1196e202.
20. Hellio MP, Peschard MJ, Cohen C, Richard M, Vignon E. Calcitonin
inhibits phospholipase A2 and collagenase activity of human osteo-
arthritic chondrocytes. Osteoarthritis Cartilage 1997;5:121e8.
21. Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprote-
gerin ligand, osteoprotegerin, and receptor activator of NF-kappaB
in giant cell tumor of bone: possible involvement in tumor cell-induced
osteoclast-like cell formation. Am J Pathol 2000;156:761e7.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.
Methods 2001;25:402e8.
23. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL,
et al. Cloning and characterization of an abundant subtype of the
human calcitonin receptor. Mol Pharmacol 1994;46:246e55.
24. Gorn AH, Lin HY, YaminM, Auron PE, FlanneryMR, Tapp DR, et al. Clon-
ing, characterization, and expression of a human calcitonin receptor
from an ovarian carcinoma cell line. J Clin Invest 1992;90:1726e35.
25. Xu J, Wang C, Han R, Pavlos N, Phan T, Steer JH, et al. Evidence of
reciprocal regulation between the high extracellular calcium and
RANKL signal transduction pathways in RAW cell derived osteo-
clasts. J Cell Physiol 2005;202:554e62.26. Jones DG, Smith RL. Stimulation of adult chondrocyte metabolism by
a thyroid-derived factor. J Orthop Res 1990;8:227e33.
27. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N,
et al. RAMPs regulate the transport and ligand speciﬁcity of the
calcitonin-receptor-like receptor. Nature 1998;393:333e9.
28. Badurski JE, SchwammW, Popko J, Zimnoch L, Rogowski F, Pawlica J.
Chondroprotective action of salmon calcitonin in experimental arthrop-
athies. Calcif Tissue Int 1991;49:27e34.
29. Behets C, Williams JM, Chappard D, Devogelaer JP, Manicourt DH.
Effects of calcitonin on subchondral trabecular bone changes and
on osteoarthritic cartilage lesions after acute anterior cruciate ligament
deﬁciency. J Bone Miner Res 2004;19:1821e6.
30. El Hajjaji H, Williams JM, Devogelaer JP, Lenz ME, Thonar EJ,
Manicourt DH. Treatment with calcitonin prevents the net loss of col-
lagen, hyaluronan and proteoglycan aggregates from cartilage in the
early stages of canine experimental osteoarthritis. Osteoarthritis Car-
tilage 2004;12:904e11.
31. Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van
Egeren A, Lenz ME, et al. Treatment with calcitonin suppresses the
responses of bone, cartilage, and synovium in the early stages of ca-
nine experimental osteoarthritis and signiﬁcantly reduces the severity
of the cartilage lesions. Arthritis Rheum 1999;42:1159e67.
32. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone?
Arthritis Rheum 2004;50:341e4.
